Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG6496 in Huntington's Disease
NCT07246941Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- RNA Therapeutics
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of RG6496 in Huntington's disease (HD) (3 arms), sponsored by Roche. Primary endpoints: Adverse Events at 38 months, Neurological Assessment at 38 months and 2 more. Started Nov 2025; status: active, not recruiting.
02
Drugs
RG6496
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT07246941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07246941.